Axial compressive strength of human vertebrae trabecular bones classified as normal, osteopenic and osteoporotic by quantitative ultrasonometry of calcaneus

Imagem de Miniatura
Arquivos
art_CESAR_Axial_compressive_strength_of_human_vertebrae_trabecular_bones_2017.PDF (1.63 MB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Título da Revista
ISSN da Revista
Título do Volume
Editora
BRAZILIAN SOCIETY OF BIOMEDICAL ENGINEERING
Autores
CESAR, R.
BOFFA, R. S.
REIFF, R. B. D. M.
NETTO, A. M.
FORTULAN, C. A.
ROLLO, J. M. D. A.
Citação
RESEARCH ON BIOMEDICAL ENGINEERING, v.33, n.2, p.91-96, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Biomechanical assessment of trabecular bone microarchitecture contributes to the evaluation of fractures risk associated with osteoporosis and plays a crucial role in planning preventive strategies. One of the most widely clinical technics used for osteoporosis diagnosis by health professionals is bone dual-energy X-ray absorptiometry (DEXA). However, doubts about its accuracy motivate the introduction of congruent technical analysis such as calcaneal ultrasonometry (Quantitative Ultrasonometry - QUS). Methods: Correlations between Bone Quality Index (BQI), determined by calcaneal ultrasonometry of thirty (30) individuals classified as normal, osteopenic and osteoporotic, and elastic modulus (E) and ultimate compressive strength (UCS) from axial compression tests of ninety (90) proof bodies from human vertebrae trabecular bone, which were extracted from cadavers in the twelfth thoracic region (T12), first and fourth lumbar (L1 and L4). Results: Analysis of variance (ANOVA) showed significant differences for E (p = 0.001), for UCS (p = 0.0001) and BQI. Spearman’s rank correlation coefficient (rho) between BQI and E (r = 0.499) and BQI and UCS (r = 0.508) were moderate. Discussion: Calcaneal ultrasonometry technique allowed a moderate estimate of bone mechanical strength and fracture risk associated with osteoporosis in human vertebrae. © 2017, Brazilian Society of Biomedical Engineering. All rights reserved.
Palavras-chave
Axial compression test, Calcaneal ultrasonometry, Correlation, Human vertebra, Osteoporosis, Trabecular bone
URI
https://observatorio.fm.usp.br/handle/OPI/25011
Referências
  1. Majdan, M., Treat-to-target in rheumatology (2015) Wiad Lek, 68, pp. 259-264
  2. The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials (2006) Arthritis Rheum, 54, pp. 421-432. , Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
  3. Bertsias, G.K., Tektonidou, M., Amoura, Z., Joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012) Ann Rheum Dis, 71, pp. 1771-1782
  4. Gladman, D.D., Ibanez, D., Urowitz, M.B., Systemic lupus erythematosus disease activity index 2000 (2002) J Rheumatol, 29, pp. 288-291
  5. Gordon, C., Sutcliffe, N., Skan, J., Definition and treatment of lupus flares measured by the BILAG index (2003) Rheumatology, 42, pp. 1372-1379
  6. Klumb, E.M., Silva, C.A., Lanna, C.C., Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis (2015) Rev Bras Reumatol, 55, pp. 1-21
  7. Houssiau, F.A., Vasconcelos, C., D'Cruz, D., Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide (2002) Arthritis Rheum, 46, pp. 2121-2131
  8. Appel, G.B., Contreras, G., Dooley, M.A., Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis (2009) J Am Soc Nephrol, 20, pp. 1103-1112
  9. Furie, R., Nicholls, K., Cheng, T.T., Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study (2014) Arthritis Rheumatol, 66, pp. 379-389
  10. Trial Group, A., Treatment of lupus nephritis with abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (2014) Arthritis Rheumatol, 66, pp. 3096-3104
  11. Corapi, K.M., Dooley, M.A., Pendergraft, W.F., Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials (2015) Arthritis Res Ther, 17, p. 110
  12. Dall'Era, M., Cisternas, M.G., Smilek, D.E., Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the Euro-Lupus Nephritis cohort (2015) Arthritis Rheumatol, 67, pp. 1305-1313
  13. Tamirou, F., Lauwerys, B.R., Dall'Era, M., A proteinuria cut-off level of 0. 7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial (2015) Lupus Sci Med, 2, p. e000123
  14. Oliveira-Santos, M., Verani, J.F., Klumb, E.M., Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil (2011) Lupus, 20, pp. 320-329
  15. Hochberg, M.C., Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus (1997) Arthritis Rheum, 40, p. 1725
  16. Chen, Y.E., Korbet, S.M., Katz, R.S., Value of a complete or partial remission in severe lupus nephritis (2008) Clin J Am Soc Nephrol, 3, pp. 46-53
  17. Contreras, G., Lenz, O., Pardo, V., Outcomes in African Americans and Hispanics with lupus nephritis (2006) Kidney Int, 69, pp. 1846-1851
  18. Isenberg, D., Appel, G.B., Contreras, G., Influence of race/ ethnicity on response to lupus nephritis treatment: The ALMS study (2010) Rheumatology, 49, pp. 128-140
  19. Collado, M.V., Dorado, E., Rausch, S., Long-term outcome of lupus nephritis class II in Argentine patients: An open retrospective analysis (2016) J Clin Rheumatol, 22, pp. 299-306
  20. Hanly, J.G., Su, L., Urowitz, M.B., A longitudinal analysis of outcomes of lupus nephritis in an international inception cohort using a multistate model approach (2016) Arthritis Rheumatol, 68, pp. 1932-1944
  21. Parikh, S.V., Nagaraja, H.N., Hebert, L., Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis (2014) Clin J Am Soc Nephrol, 9, pp. 279-284
  22. Korbet, S.M., Schwartz, M.M., Evans, J., Severe lupus nephritis: Racial differences in presentation and outcome (2007) J Am Soc Nephrol, 18, pp. 244-254
  23. Austin, H.A., Muenz, L.R., Joyce, K.M., Prognostic factors in lupus nephritis. Contribution of renal histologic data (1983) Am J Med, 75, pp. 382-391
  24. Appel, G.B., Cohen, D.J., Pirani, C.L., Long-term follow-up of patients with lupus nephritis. A study based on the classification of the world health organization (1987) Am J Med, 83, pp. 877-885
  25. Tesar, V., Moderator's view: Cyclophosphamide in lupus nephritis (2016) Nephrol Dial Transplant, 31, pp. 1058-1061

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOT
Artigos e Materiais de Revistas Científicas - HC/IOT
Artigos e Materiais de Revistas Científicas - LIM/41